Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age‐related macular degeneration: a review of current practice
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
We review the fundamental changes that are now occurring to the management of neovascular (wet) age-related macular degeneration (AMD). An improved understanding of the role of vascular endothelial growth factor (VEGF) in the genesis of choroidal neovascular membranes has led to the creation and use of intravitreous anti-VEGF antibodies (bevacizumab and ranubizumab) and an aptamer (pegaptanib) in the treatment of these lesions. These new intravitreous injections for AMD have supplanted previous treatments in both efficacy and safety and are now the standard of care for neovascular AMD. We discuss the biochemistry of the anti-VEGF pathway. While there is substantial evidence for the use of ranubizumab and pegaptanib, the intravitreous administration of bevacizumab has not been tested in randomised controlled clinical trials. We review the evidence base for all three agents and the patho-physiological basis for adverse reactions to intravitreous VEGF blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“The genes encoding bevacizumab were recombined with those encoding a human antibody molecule (humanisation) and expressed in a cultured mammalian cell line (Chinese hamster ovary cells) to yield a hybrid antibody that closely resembles a human antibody.(24,25,30) Like ranibizumab, bevacizumab binds to all isoforms of…”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Age-related macular degeneration
de Jong, P. T. V. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062326 · Cited by 787
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
FRANK, R. N., AMIN, R. H., ELIOTT, D., PUKLIN, J. E., & ABRAMS, G. W. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72066-5 · Cited by 366
Evans, J. R., & Lawrenson, J. G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000254.pub4 · Cited by 335
Cited by
Kunchithapautham, K., & Rohrer, B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.214593 · Cited by 71
Rohrer, B., Coughlin, B., Kunchithapautham, K., Long, Q., Tomlinson, S., Takahashi, K., & Holers, V. M. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.016 · Cited by 62
Han, J. W., Yang, J. Y., Kim, Y., An, S., Yoo, E., Park, I. H., Lee, S.-W., Lee, H.-J., Lee, T. G., Jung, W. H., et al. (2026) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2026.103101 · Cited by 1
Metadata
- Authors
- Van wijngaarden, P., & Qureshi, S. H.
- Venue
- Clinical and Experimental Optometry
- Publisher
- Informa UK Limited
- Published
- 2008-09-01
- Volume
- 91
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0816-4622 (ISSN-L)
- 1444-0938
- OpenAlex
- W2013055036
- Cited by
- 63
- References
- 14
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age‐related macular degeneration: a review of current practice. https://app.cochat.ai/papers/10.1111/j.1444-0938.2008.00305.x
- The paper
- Van wijngaarden, P., & Qureshi, S. H. (2008). Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age‐related macular degeneration: a review of current practice. Clinical and Experimental Optometry. https://doi.org/10.1111/j.1444-0938.2008.00305.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.